West Pharmaceutical Services

West Pharmaceutical Services, a US-based company in the Pharmaceutical Preparation Manufacturing industry, has established significant climate commitments and reported its greenhouse gas emissions across various scopes.

For the 2025 reporting year, West Pharmaceutical Services reported a total of approximately 636.7 million kg CO2e. This breaks down into approximately 33.8 million kg CO2e for Scope 1 emissions and approximately 64.0 million kg CO2e for Scope 2 emissions. Scope 3 emissions were substantial, totalling approximately 538.9 million kg CO2e, with purchased goods and services accounting for the largest portion at approximately 391.9 million kg CO2e.

In the preceding year, 2024, the company's total emissions were approximately 583.9 million kg CO2e. Scope 1 emissions were approximately 31.4 million kg CO2e and Scope 2 emissions were approximately 70.0 million kg CO2e. Scope 3 emissions for 2024 amounted to approximately 513.9 million kg CO2e.

West Pharmaceutical Services has set ambitious reduction targets. Through the Science Based Targets initiative (SBTi), the company has committed to reducing absolute Scope 1 greenhouse gas (GHG) emissions by 42.0% by 2030, using a 2024 base year. Similarly, Scope 2 GHG emissions are targeted for a 42.0% absolute reduction by 2030, also from a 2024 base year. Furthermore, a significant commitment has been made to reduce absolute Scope 3 GHG emissions by 37.5% by 2035, again based on a 2024 baseline. These targets are recognised as being consistent with the reductions required to limit warming to 1.5°C.

Earlier commitments included a goal to reduce absolute emissions by 10% between 2019 and 2023 for both Scope 1 and Scope 2. More recently, the company reported a target to reduce absolute emissions by 40% by 2030, with a specific aim to achieve 50% renewable electricity and improve energy efficiency by 3% year-on-year.